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Case Report
A 75-year-old male, with a medical history of diabetes,
hypertension, coronary artery disease, status post coronary
artery bypass graft, and left-sided breast cancer, status post left
breast mastectomy, was transferred from an outside hospital
with complaints of a month of constipation, nausea and
vomiting. The patient presented to an OSH a month prior with
recent onset of constipation, with no bowel movements for 10
days, changed from his usual habit of daily bowel movements.
He initially responded to lactulose with a bowel movement and
was discharged on a regimen of stool softeners and laxatives;
however, upon returning home, he was again unable to move
his bowels despite his bowel regimen and developed diffuse
abdominal pain, nausea and vomiting secondary to distension.
An outpatient esophagogastroduodenoscopy (EGD) showed
that the patient had a normal esophagus and a large amount
of retained food in the stomach, concerning for gastroparesis.
This finding was thought to be secondary to his diabetes, despite
his well-controlled blood sugars and a hemoglobin A1c of 7.0
%. After two further weeks of constipation, the patient was
readmitted to the OSH with abdominal pain, intractable nausea
and vomiting, as well as a 20-25 lbs weight loss since his symptoms
began. Imaging showed colonic gaseous distention, with the
cecum dilated to 9.5 cm, and an un-prepped sigmoidoscopy
was performed, showing no inflammation, polyps or masses; of
note, a screening colonoscopy done 4 months prior identified
and removed multiple benign polyps. A CT scan of his abdomen
and pelvis also did not show any obstructing colonic masses. He
was presumed to have colonic pseudo-obstruction, or Ogilvie
Syndrome. Erythromycin was started without effect. He was
subsequently given neostigmine, which was also unsuccessful in
relieving his symptoms. The patient was then referred to another
OSH for further workup. A 4-day gut motility study showed a
pan-GI dysmotility disorder. Furthermore, a gastric emptying
study revealed markedly delayed gastric emptying of both
solid and liquid foods, but defecography was entirely normal.
Non-contrast CTs of the chest, abdomen and pelvis again did
not identify any masses or bowel obstruction, but did show
enlarged precarinal lymph nodes and prostatomegaly, as well
as small thyroid nodules bilaterally. As the patient continued to
fail to have a bowel movement and could not tolerate a diet,
he was started on total parenteral nutrition and was transferred
to Thomas Jefferson University Hospital (TJUH) for further
evaluation.
On presentation to TJUH, the patient complained of occasional
diffuse abdominal pain and distention, as well as nausea. He
had not had any vomiting since he stopped eating when he was
started on TPN. He denied any swallowing difficulty but did
complain of constantly spitting up clear sputum. He had not
had a bowel movement in more than 4 weeks since his initial

response to lactulose at the first OSH. He had lost 30 lbs in the
4 weeks since his symptoms began. His review of systems was
other wise negative.
As noted previously, the patient’s medical history is significant
for hypertension, hyperlipidemia, coronary artery disease status
post coronary artery bypass graft 15 years ago, well-controlled
type 2 diabetes diagnosed 8 years ago and benign prostate
hypertrophy. He also had left-sided breast cancer 7 years ago,
treated with a left mastectomy and a 5-year course of tamoxifen.
Social history indicated no current abuse of alcohol, tobacco,
or illegal drugs, though he admitted to a 20-pack-year smoking
history, having quit 35 years ago. He is a long time employee of
a steel company and also owns a farm in eastern Pennsylvania.
Family history is significant for breast cancer in his sister and
stomach cancer in his mother.
The patient’s admission labs were unremarkable, with a normal
complete blood count, prothrombin time, partial thromboplastin time, basic metabolic panel and electrolytes. His thyroid
function tests were also within normal limits. He did have an
elevated prostate specific antigen of 11.6 ng/mL. On physical
examination, the patient was afebrile with normal vital signs.
He was alert and oriented to person, place and time, and in no
distress. Of note, he had post-CABG median sternotomy scar
that was well healed, as well as a left-sided scar on his left chest
remnant of a mastectomy. His abdomen was soft with active
bowel sounds, but diffusely distended and diffusely tender to
palpation, without guarding or rebound. The remainder of his
exam was otherwise benign.

Hospital Course
The patient was admitted for workup of his GI dysmotility.
Initial imaging with an obstruction series again showed no
evidence of an intestinal obstruction. A subsequent CT of the
abdomen and pelvis demonstrated a normally appearing small
and large bowel and identified no cause of his symptoms. He
then underwent an EGD, which found esophagitis at the level
of his gastroesophageal junction; however, the remainder of his
esophagus appearing normal. His stomach had retained fluid
and food in the fundus despite having not eaten for almost 2
weeks. The remainder of his stomach exam was remarkable
for a spastic pylorus, which was treated with botox injection.
There was no improvement in the patient’s gastric motility,
however, and his symptoms of nausea, abdominal fullness and
constipation persisted.
The patient was seen by the Neurology Service to evaluate the
possibility of autonomic dysfunction as the etiology of his GI
dysmotility. He was found to have orthostatic hypotension with
a supine blood pressure of 182/80 mmHg and heart rate of 121
beats per minute and an upright blood pressure of 122/65 mmHg
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with a heart rate in the 180s beats per minute. Though the patient
had previously been given a trial of neostigmine at the OSH, he
was empirically started on pyridostigmine 60 mg three times a
day. He received 5 days total of pyridostigmine, without relief
of his constipation. The medication was promptly stopped on
the fifth day when daily monitoring EKG showed development
of first-degree heart block and bradycardia. EKGs following
the cessation of pyridostigmine showed improvement of his
PR interval and resolution of his bradycardia. Acetylcholine
receptor binding antibody was checked and returned as normal.
To further evaluate for autonomic GI dysmotility, a ganglionic
acetylcholine receptor binding antibody titer was sent, which
was also negative.
The Rheumatology Service was consulted regarding the
possibility of an autoimmune etiology, such as systemic
sclerosis, causing his GI dysmotility. The patient’s antinuclear
antibody titer was positive, with a titer of 1:320 and a speckled
pattern; however, the rest of his rheumatologic serologies,
including anti-double stranded DNA, anti-sm, anti-RNP,
Sjogren’s anti-SCL 70, anti-centromere and rheumatoid factor,
were negative. Therefore, it was deemed very unlikely that
his GI dysmotility was secondary to an autoimmune process.
The possibility of infiltrative diseases, such as amyloidosis,
causing his GI dysmotility was also examined; however, his
serum and urine protein electrophoreses were both negative.
Environmental exposures were also explored, given the patient’s
social history of living on a farm. Lyme antibody and a heavy
metal drug screen were negative.
There was significant suspicion that the patient’s GI dysmotility
may be secondary to a paraneoplastic syndrome. Accordingly, he
was evaluated with a serum paraneoplastic panel. This screen was
positive for the anti-Hu (ANNA-1) antibody, which is associated
with small cell lung cancer, prostate, and breast cancer. Though
CT scans of the patient’s chest, abdomen and pelvis were
negative for any masses, some enlarged precarinal lymph nodes
and an enlarged prostate were noted. Given the patient’s history
of breast cancer, as well as elevated PSA (11.6 ng/mL) and a
remote smoking history, the patient was recommended to get an
outpatient positron emission tomogram (PET) scan to workup
any possible occult malignancy. He was also recommended
have biopsies done of his precarinal lymph nodes and his
prostate, regardless of the PET findings. The patient was started
empirically on intravenous steroids, along with lubiprostone to
increase GI secretions. Approximately 5 days after being started
on methylprednisolone 40 mg daily, and lubiprostone 24 mg
twice a day, he was able to move his bowels, with a total of 4
bowel movements that day, suggesting that his symptoms were
secondary a paraneoplastic syndrome from an occult malignancy.
Though the patient did not continue to have bowel movements
on the steroids and was still unable to tolerate a solid diet, he was
discharged home with oral steroids and on a full liquids diet in
order to facilitate the completion of an outpatient PET scan to
screen for the highly-suspected occult malignancy.

42

Background/Epidemiology
Intestinal dysmotility has long been recognized as a paraneoplastic syndrome in small cell carcinoma of the lung (Ahmed
and Schuffler). In 1991, Lennon et al. first recognized the
association of gastrointestinal dysmotility and ANNA-1.5

Clinical Characteristics/Differential
Diagnosis/Serological Testing And Other Studies
The presence of ANNA-1 (or anti-Hu) can produce a variety of
different clinical presentations depending on which part of the
gastrointestinal tract is affected. Pseudo-achalasia, gastroparesis
and intestinal pseudo-obstruction have all been linked to the
autoantibody anti-Hu. 5,7,13,16,17 The autoantibodies found in
patients with paraneoplastic GI dysmotility are different from
those thought to be responsible for primary achalasia in that the
former may affect neurons throughout the GI track. Therefore,
many patients have a pan-dysmotility, although usually
one of the above disorders will present as the predominant
symptom. Gastroparesis is the most common presentation of
GI dysmotility secondary to ANNA-1 antibodies and has been
reported to resolve completely upon resection of associated
tumors.7 These patients present with a marked delay of gastric
emptying in the absence of gastric outlet obstruction. This
produces symptoms of nausea, vomiting, early satiety, epigastric
fullness and retained food in the stomach. On the other hand,
patients with ANNA-1-induced pseudo-obstruction will
present with either recurrent or persistent symptoms of bowel
obstruction. Chronic neurogenic intestinal pseudo-obstruction
is defined as severe impairment of intestinal motility producing
symptoms of mechanical obstruction in the absence of any
organic obstacle to intestinal transit.3 An obstructive etiology
was ruled out in our patient via obstructive series films, CT of
the abdomen and pelvis, and colonoscopy.
The diagnosis of paraneoplastic GI dysmotility requires a
high index of suspicion. There are many alternative diagnoses
that need to be considered during the work-up of achalasia,
gastroparesis and chronic pseudo-obstruction. The differential
diagnosis of gastrointestinal neuropathies associated with motor
dysfunction include developmental, degenerative (idiopathic,
paraneoplastic and infectious), toxic or drug induced, or
systemic disease related (diabetes mellitus, scleroderma,
amyloidosis) neuropathies. Cytomegalovirus, herpes simplex
virus and trypanosome cruzi (Chaga’s disease) are the infections
most often associated with degenerative inflammatory
neuropathies. 3 In our case, an investigation for infectious
etiologies was negative including CMV PCR and stool studies.
The patient remained afebrile and never had an elevated white
blood cell count throughout the hospital course. A heavy metal
drug screen came back negative and a thorough review of our
patient’s medications failed to find a culprit. Negative serum
and urine protein electrophoresis studies and a hemoglobin A1c
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of 7 % helped to rule out infiltrative processes and a diabetic
autonomic neuropathy, respectively.
Paraneoplastic gastrointestinal dysmotility can be attributed to
the recognition of the RNA binding protein, Hu, by anti-neuronal
nuclear antibody (ANNA-1). These autoantibodies are thought
to target tumor antigens that show cross-reactivity with
myenteric neurons.1 Small cell lung carcinoma and thymoma
are the most common neoplasms associated with paraneoplastic
intestinal dysmotility due to ANNA-1 or anti-Hu antibodies.4,5,15
However, associaton with lymphomas and tumors of the breast,
prostate and ovary have also been reported.7
Lee et al. published a case series of patients with paraneoplastic
GI motor dysfunction and found that small cell carcinoma of
the lung (SCLC) presented an average of 8.7 months after the
onset of GI symptoms in ANNA-1 positive individuals. This
is opposed to the other associated malignancies (lymphoma,
anaplastic lung adenocarcinoma and ovarian cancer) in which
GI symptoms began an average of 14 months after the tumor
was diagnosed. Of note, the latter individuals were seropositive
for PCA-1 or N-type calcium antibodies rather than ANNA-1.
In the same study, it was shown that 83% of the cases involved
a second manifestation of a paraneoplastic disorder, including
sympathetic and/or parasympathetic failure, peripheral
sensorimotor neuropathy, syndrome of inappropriate
anti-diuretic hormone, or cerebellar degeneration.6 Therefore,
the presence of a neurologic disorder combined with a GI
dysmotility may lead the clinician to search for underlying
malignant causes. Our patient presented with asymptomatic
orthostatic hypotension, which provided a clue that led our
team to investigate neurologic causes of gastroparesis and
pseudo-obstruction.
Breast tumors have rarely been associated with paraneoplastic
GI dysmotility. One patient with bilateral breast cancer, which
was treated with chemotherapy, achieved improvement of her
concomitant gastroparesis as her tumor went into remission.
The patient was presumed to have a paraneoplastic cause of
her GI dysmotility and Berghmans et al. hypothesized that
auto-antibodies were responsible due to the lack of mechanical
obstruction and close clinical correlation.2 Our patient’s past
medical history of the breast carcinoma prompted us to wonder
if his clinical anti-Hu syndrome was a manifestation of his
tumor recurrence. This is further supported by reports that
gastrointestinal paresis and intestinal pseudo-obstruction may
be the first sign of a recurring thymoma.4

Management (Cancer Workup) and Treatment
In 13% of patients with SCLC , an unrelated primary malignancy
exists, most commonly renal cell carcinoma.7 This suggests that
a work-up for SCLC should still be pursued despite the presence
of an alternate primary tumor. Our patient had a remote history
of a breast tumor for which he had a mastectomy and tamoxifen
therapy. He also had an elevated PSA and 6.8 cm prostate on CT

scan that led us to consult urology for prostate biopsy. However,
the procedure could not be performed secondary to a urinary
tract infection that complicated the patient’s hospital course.
Despite the evidence for other sources of a paraneoplastic
tumor, our clinical suspicion for a SCLC remained high.
Kashyap et al. suggests that serial CT of the chest every 6
months is one conservative management strategy if the initial
CT is negative. A PET scan with biopsy of suspicious nodes is
an alternative approach. Finally, if the clinical picture is highly
suggestive of an occult malignancy despite a negative initial
work-up, bronchoscopy or mediastinoscopy may be offered
to the patient.1 In the case of our patient, his initial chest CT
was negative except for a few enlarged precarinal lymph nodes.
It was decided that a lymph node biopsy would be offered to
the patient if the PET scan failed to show a source. PET scan
will allow simultaneous investigation for a breast carcinoma,
prostate tumor or an occult SCCL. Finally, a full thickness
intestinal biopsy may aid in this diagnosis by demonstrating
an inflammatory infiltrate of lymphocytes and plasma cells that
inhabit the myenteric plexus and lead to destruction of neural
elements.3 However, a tissue diagnosis is not always necessary
when gastrointestinal dysmotility occurs in conjunction with the
presence of a tumor and circulating autoantibodies. Therefore,
we suggest that serologic and other non-invasive tests take place
first before considering this procedure.
There is no standard of care for the treatment of antibodyassociated GI dysmotility, due to the rarity of the disease and
the difficulty measuring response to therapy. Many different
regimens combining prokinetic agents, systemic steroid therapy
and other immunosuppressants have been reported. Pulse
doses of neostigmine (2 mg administered intravenously) led
to peristalsis and relief of colonic distention in a patient with
positive ANNA-1 with paraneoplastic encephalomyelitis and
autonomic neuropathy.12 A steroid taper starting at 60 mg per
day of methylprednisolone led to a remission of symptoms for
one year in a patient with idiopathic mesenteric ganglionitis.9 A
regimen of pulse steroids using methylprednisolone 100mg IV
for three days improved symptoms of intestinal subocclusion
in another patient with positive ANNA-1. 11 On the other
hand, Lucchinetti et al. reported that 38 patients with positive
ANNA-1 and gastrointestinal dysmotility failed to respond to
adrenal corticosteroids, plasma exchange, intravenous immune
globulin (IVIG) or cyclophosphamide.7 Our patient had a limited
response to neostigmine, pyridostigmine and erythromycin.
However, after starting lubiprostone and intravenous steroids
our patient did have a bowel movement and was able to tolerate
a full liquid diet. He was sent home on a taper of oral steroids,
but relapsed a few weeks later, requiring another hospitalization
for intractable nausea, vomiting and abdominal pain.
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